SeaStar Medical to Report Fourth Quarter and Year-End 2025 Financial Results on March 25, 2026
Rhea-AI Summary
SeaStar Medical (Nasdaq: ICU) will report fourth quarter and year-end 2025 financial results after market close on Wednesday, March 25, 2026. A live webcast and conference call will follow at 4:30 p.m. ET / 2:30 p.m. MT, with a replay available after 7:30 p.m. ET.
Preregistration is required to join the live call; a pin and dial-in information will be provided upon registration.
Positive
- None.
Negative
- None.
News Market Reaction – ICU
In the Mar 19 session, ICU declined 3.40%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 05 | Post-approval study update | Positive | +2.8% | Completed required FDA SAVE Registry enrollment for QUELIMMUNE pediatric AKI safety. |
| Feb 09 | Clinical data publication | Positive | -2.0% | Published positive real-world QUELIMMUNE outcomes in Pediatric Nephrology. |
| Jan 29 | Investor conference | Neutral | -2.3% | Announced CEO presentation at Noble Capital Markets virtual equity conference. |
| Jan 07 | Corporate milestones | Positive | -4.7% | Outlined 2026 commercial, clinical, and regulatory milestones for QUELIMMUNE and SCD. |
| Jan 06 | Investor conference | Neutral | -0.4% | Announced Biotech Showcase 2026 presentation and investor meetings around JPM conference. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive clinical and corporate updates have seen mixed or negative next-day moves, while neutral conference-related news has generally coincided with modest declines.
Over the last few months, SeaStar Medical has focused on advancing QUELIMMUNE and investor visibility. On Mar 5, 2026, it completed required FDA SAVE Registry enrollment, and on Feb 9, 2026 it reported positive real‑world QUELIMMUNE data. Earlier in January, management outlined 2026 milestones and participated in investor conferences. Against this backdrop of clinical and commercial progress plus ongoing capital-structure work, the newly announced Q4 and year-end 2025 earnings date fits into a pattern of regular updates on execution.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DENVER, March 18, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that it will report its fourth quarter and year-end 2025 financial results after market close on Wednesday, March 25, 2026, and host a webcast and conference call to discuss its financial results and business progress.
| Date/Time: | Wednesday, March 25, 2026, at 4:30 p.m. ET / 2:30 p.m. MT |
| Webcast: | The live webcast and replay can be found here. |
| Register for the call: | Preregistration is required to attend the live call and can be accessed here. A pin code and dial in number will be provided with registration. |
A replay of the call will be available after 7:30 p.m. ET and can be accessed here.
About SeaStar Medical
SeaStar Medical is a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life. SeaStar Medical’s first commercial product, QUELIMMUNE (SCD-PED), was approved in 2024 by the U.S. Food and Drug Administration (FDA). It is the only FDA approved product for the ultra-rare condition of life-threatening Acute Kidney Injury (AKI) due to sepsis or a septic condition requiring renal replacement therapy (RRT) in critically ill pediatric patients. SeaStar Medical’s Selective Cytopheretic Device (SCD) therapy has been awarded Breakthrough Device Designation for six therapeutic indications by the FDA, enabling the potential for a speedier pathway to approval and preferable reimbursement dynamics at commercial launch. The company is currently conducting the NEUTRALIZE-AKI pivotal clinical trial of its SCD therapy in adult patients with AKI requiring continuous renal replacement therapy, a life-threatening condition with no effective treatment options that impacts over 200,000 adults in the U.S. annually.
For more information visit www.seastarmedical.com or visit us on LinkedIn or X.
Contact:
SeaStar Investor Relations:
IR@SeaStarMed.com
